Saturday, May 12, 2018 12:41:25 PM
About the legal and political issues. I didn't consider any of that. If they come and when they come, this will just add to the stability of the operation and stock price. I don't consider it because I know it's coming but don't know when..And yes there is plenty of cash waiting for all these things to happen.
When I asked the CEO about when to break even. (I asked in three 3 different occasions). The answer was the same. I implied that the expansion was needed to achieve breakeven and he corrected me saying that with the CURA oil operation alone he would reach break even. That he was $200K per month shy of break even. That no expansion was needed for that. So the operation will be profitable within months. Maybe 4 to 6 when the royalties from CURA reach $250-$300K. Let's not forget that the efficiency is improving so TECO is probably selling $575-$600 a month.
The tissue propagation process is very valuable but it has not been and will not be patented in the near future. It is still been develop to achieve 90%+ efficacy. It is a fundamental part of the medical grade oil business and it holds plenty value once cannabis becomes legal. I think this part of the business will be develop in partnership with LSU from what I could understand. Selling small certified plants could be a big business.. according to the CEO.
Recent GBLX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2024 09:39:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 10:07:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/10/2023 02:00:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:15:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 06:31:48 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/02/2023 08:18:58 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/14/2023 08:12:47 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 06/30/2023 12:00:24 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM